Navigation Links
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)

Will Begin Promotion in October At U.S. Psychiatric Congress

PARSIPPANY, N.J., Sept. 11 /PRNewswire/ -- Validus Pharmaceuticals, Inc. announced today that it has acquired the unique Bipolar Disorder treatment, Equetro(R) (carbamazepine) extended release capsules, from Shire plc.

EQUETRO(R) is a treatment for the acute manic and mixed episodes associated with Bipolar-1 Disorder -- a condition where patients experience extended periods of exaggerated highs in addition to the extended lows commonly associated with Bipolar Disorder. Equetro's patented advanced drug delivery technology also provides patients with the convenience of twice-daily dosing.

"This is a watershed moment in the commercialization of Validus Pharmaceuticals" stated James Hunter, Validus President & CEO. "Equetro(R) provides mental health professionals with an important treatment option in the management of Bipolar Disorder. Equetro(R) also fits well within our growing product portfolio which includes Marplan(R) (isocarboxazid), the classic MAO- inhibitor for treatment-resistant depression."

Validus Pharmaceuticals will begin active promotion of Equetro(R) during the U.S. Psychiatric & Mental Health Congress -- one of the nation's largest gatherings of mental health professionals -- in Orlando, FL in early October.

About Validus Pharmaceuticals:

Validus Pharmaceuticals is a specialty pharmaceutical company founded in Parsippany, NJ in 2007 to serve the unmet needs of patients with central nervous system (CNS) diseases. The company pursues this mission with targeted and focused marketing efforts and active acquisition and in-licensing programs aimed at underutilized CNS products that have important future potential. Validus is a portfolio company of the Konanda Pharma Fund I, L.P. in New York City. Please log-on to for additional information.

About Marplan(R)

Please go to the Marplan(R) website for Full Prescribing Information, including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO-inhibitors are contraindicated with certain drugs, and potential hypertensive crises may occur with tyramine containing foods. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially within the first few months of therapy.

About Equetro(R)

Please see complete Prescribing Information for Equetro at EQUETRO(R) contains carbamazepine. If you are currently taking another medication that contains carbamazepine, do not begin taking Equetro(R) without discussing this with your healthcare provider. Products that contain carbamazepine have been associated with rare but serious types of blood disorders. People with Bipolar Disorder have an increased risk for suicide. It is important to discuss risk factors for suicide with your healthcare provider.

About Konanda Pharma Fund I, L.P.

Konanda Pharma Fund I, L.P. is an investment fund that is managed by Konanda Pharma Partners, LLC, based in New York City. The Fund acquires mature branded drugs through portfolio companies which it owns and operates. Please log-on to for additional information.

SOURCE Validus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF expands license agreement with Advanced Cell Technology
4. Verizon expands broadband service in Wisconsin
5. Bandwidth provider expands in Milwaukee
6. Wisconsins biodiesel network expands
7. Quad/Graphics expands reach in western states
8. University of South Florida expands GE Healthcare relationship
9. Metavante expands healthcare payments division
10. Fiserv expands services to health plan market
11. Bone Care expands patent protection of core drug offering
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
Breaking Biology Technology:
(Date:11/26/2015)... Research and Markets ( ) has ... - Technology and Patent Infringement Risk Analysis" report ... --> Fingerprint sensors using capacitive technology represent ... sensor vendor Idex forecasts an increase of 360% of ... and of the fingerprint sensor market between 2014 and ...
(Date:11/20/2015)... November 20, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Pereira , was recently interviewed on The RedChip ... on this weekend on Bloomberg Europe , Bloomberg ... --> NXTD ) ("NXT-ID" or the "Company"), ...
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
Breaking Biology News(10 mins):